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Kidney injury molecule-1 (Kim-1) has been qualified by the
Food and Drug Administration and European Medicines
Agency as a highly sensitive and specific urinary biomarker to
monitor drug-induced kidney injury in preclinical studies
and on a case-by-case basis in clinical trials. Here we report
the development and evaluation of a rapid direct
immunochromatographic lateral flow 15-min assay for
detection of urinary Kim-1 (rat) or KIM-1 (human). The
urinary Kim-1 band intensity using the rat Kim-1 dipstick
significantly correlated with levels of Kim-1 as measured
by a microbead-based assay, histopathological damage,
and immunohistochemical assessment of renal
Kim-1 in a dose- and time-dependent manner. Kim-1 was
detected following kidney injury induced in rats by cadmium,
gentamicin, or bilateral renal ischemia/reperfusion. In
humans, the urinary KIM-1 band intensity was significantly
greater in urine from patients with acute kidney injury than in
urine from healthy volunteers. The KIM-1 dipstick also enabled
temporal evaluation of kidney injury and recovery in two
patients who developed postoperative acute kidney injury
following cytoreductive surgery for malignant mesothelioma
with intraoperative local cisplatin administration. We hope
that future, more extensive studies will confirm the utility of
these results, which show that the Kim-1/KIM-1 dipsticks
can provide a sensitive and accurate detection of Kim-1/KIM-1,
thereby providing a rapid diagnostic assay for kidney damage
and facilitating the rapid and early detection of kidney injury
in preclinical and clinical studies.
Kidney International (2009) 76, 108–114; doi:10.1038/ki.2009.96;
published online 22 April 2009
KEYWORDS: biomarkers; cadmium; dipstick; ischemia/reperfusion injury;
kidney toxicity; Kim-1
The incidence of acute kidney injury is steadily increasing
and the tools available for early detection are insensitive and
have limited specificity. In addition it is estimated that by
2015, more than 700,000 individuals in the United States will
have end-stage renal disease and more than 107,000 end-
stage renal disease-related deaths will occur annually.1
Acute kidney injury (AKI) is also considered an important
risk factor for progression to end-stage renal disease.2 Early
detection of AKI before significant loss of kidney function
would permit more timely diagnosis of AKI, prediction of
injury severity, and safety assessment during drug develop-
ment. Current metrics such as serum creatinine (SCr)
and blood urea nitrogen (BUN) lack the sensitivity
and/or specificity to adequately detect kidney damage.2–4
Recently, the Critical Path Institute’s Preventive Safety
Testing Consortium (PSTC) identified kidney injury
molecule-1 (Kim-1 or KIM-1 in humans) as an early
diagnostic biomarker for monitoring acute kidney tubular
toxicity in preclinical studies and the FDA and EMEA
encouraged its use for safety monitoring on a case-by-case
basis in clinical trials (http://www.fda.gov/bbs/topics/NEWS/
2008/NEW01850.html). In a multisite preclinical rat toxicol-
ogy study involving 17 studies, the consortium showed that
urinary Kim-1 not only outperformed the conventional
markers such as BUN, SCr and urinary NAG for assessing
renal injury, but did so achieving a receiver operator
characteristics-area under the curve of 0.91–0.99, the highest
performing biomarker of all those that have been examined
to date.5 Urinary Kim-1 has been shown to be a sensitive and
early diagnostic indicator of renal injury in a variety of acute
and chronic kidney injury models.6–11 Human studies have
confirmed the promise of KIM-1 for the diagnosis and
prediction of outcome of AKI.12–15
Urinary Kim-1 measurements have been performed
using ELISA assays or microsphere-based Luminex xMAP
technology5,14 that requires 3–4 h of assay time and is
dependent on a large analyzer.16 The objective of this study
was to develop and evaluate a greater ease-of-use direct
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lateral flow immunochromatographic assay that has visual
read out and is sensitive, specific, and high throughput
thereby allowing rapid (within minutes) point of care
detection of urinary Kim-1 in rats and humans.
Development and evaluation of rat and human RenaStick
Colloidal gold nanoparticles were coated with previously
tested mouse monoclonal anti-Kim-1 antibody against rat
Kim-1 ectodomain or rabbit polyclonal antibody against
human KIM-1.5,7,14 When the sample containing Kim-1 is
added to the sample well, the colloidal sphere complex bound
to Kim-1 rapidly migrates by capillary action through a
nitrocellulose membrane to a test-line that is coated with
another epitopically distinct antibody against Kim-1. The
presence of detectable levels of the Kim-1 in the test sample
results in the formation of a dark red test-line within minutes
as the gold spheres containing Kim-1 are deposited on the
test line (Supplementary Figure S1a). The assay range was
found to be linear from 1 to 20 ng/ml (n¼ 4) (Supplemen-
tary Figures S1b–c and S2a–b). The lower limit of detection
was 0.5 ng/ml for rat RenaStick and 0.8 ng/ml for human
RenaStick (n¼ 4). The analytical recovery for rat and human
Kim-1 was within the acceptable range from 78 to 108% for
5 ng/ml (Supplementary Figures S1d and S2c) and 75 to
106% for 1 ng/ml (data not shown).
Evaluation of rat RenaStick in preclinical models of kidney
injury
We evaluated whether cadmium (Cd)-induced nephrotoxi-
city can be sensitively detected by RenaStick. Cadmium is a
widely disseminated industrial and environmental pollutant.
The kidney is the primary target of toxicity following chronic
low levels of exposure.10 In control rats urinary Kim-1 levels
were undetectable (Figure 1a), consistent with the results of
the microbead-based assay (Supplementary Table S1), and
consistent with the absence of histological damage (Figure
1f), and lack of kidney Kim-1 protein expression (Figure 1j).
Kim-1 was detected after 0.6 mg/kg/day (Figure 1b) of Cd
administration for 5 days/week for 4 weeks with a further
increase seen following 1.2 mg/kg/day (Figure 1c and e) or
2.4 mg/kg/day (Figure 1d and e). The intensity of the Kim-1
band correlated very well with the levels of Kim-1 as
measured by microbead-based assay (Supplementary
Table S1a), histopathological damage (Figure 1g–i), and renal
Control 0.6 mg/kg
Cadmium
1.2 mg/kg 2.4 mg/kg
500
250
0
Control 0.6 1.2 2.4
Cadmium (mg/kg)
Cadmium
1.2 mg/kg 2.4 mg/kg0.6 mg/kgControl
H
&E
Ki
m
-1
*
*
Ba
nd
 in
te
ns
ity
 u
ni
ts
Figure 1 | Evaluation of rat RenaStick to detect urinary Kim-1 in cadmium induced nephrotoxicity model. Urinary Kim-1
measurements using rat RenaStick (a–e), histological damage (f–i), and Kim-1 immunostaining (j–m) following cadmium-induced kidney
injury. Male Sprague Dawley rats (n¼ 4/group) were injected subcutaneously with varying doses of CdCl2 (Cd dose of 0.6, 1.2, or 2.4 mg/kg)
or saline 5 days per week for 4 weeks. (a–d) After 4 weeks, rats were placed in metabolic cages and urine was collected. Seventy microliters
of urine sample from each rat was mixed with 70 ml of TRIS-buffered saline solution, added to the RenaStick sample well, and incubated for
15 min. (e) Each RenaStick was scanned using a CAMAG Thin Layer Chromatography scanner and the densitometric units obtained were
plotted. *Statistically higher than control/sham (Po0.05). (f–i) At necropsy, samples of both kidneys were isolated from each animal and
placed in 10% neutral buffered formalin (NBF) for hematoxylin and eosin (H&E) staining and histology assessment. (j–m) In addition, non-
fixed cryosections of the kidney tissue were processed for the immunoflourescent visualization of Kim-1. (f and j) Control, (g and k) 0.6 mg
Cd/kg, (h and l) 1.2 mg Cd/kg, (i and m) 2.4 mg Cd/kg. All fields were chosen from the outer renal cortex. Arrows in panels g–i indicate
retraction and sloughing of cells, tubular congestion, and necrosis. The fluorescent images in panels k–m indicate Kim-1 staining in the
apical membrane of the proximal tubules of rats treated with cadmium in similar fields of the outer renal cortex.
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Kim-1 immunostaining (Figure 1k–m). Even the individual
variability among the four rats in the same group was clearly
distinguished by the RenaStick band intensities and corre-
lated with the microbead assay, demonstrating the sensitivity
of the RenaStick.
Gentamicin is an important antibiotic with nephrotoxic side
effects in humans.17 Gentamicin administration for 9 days
resulted in a distinct dose-dependent increase in the rat urinary
Kim-1 band intensity paralleling the Kim-1 values measured
using the microbead-based method (Figure 2a–c, Supplemen-
tary Table S1b). The conventional markers of kidney injury,
BUN and SCr, were elevated significantly only following the
120 mg/kg/day dose (Figures 2e and 2f) when significant
tubular degeneration and necrosis was observed histologically
(Figure 2i). Mild histological damage, as defined by single-cell
necrosis, dilation of tubules, and basophilia, was evident in the
40 mg/kg per day group (Figure 2h). This milder injury was
sensitively detected by the RenaStick assay for urinary Kim-1
(Figure 2b and d, Supplementary Table S1b).
In a mild model of ischemia/reperfusion (I/R), RenaStick
revealed B4-fold increase in urinary Kim-1 as compared
with sham at 9 h after 20 min of bilateral I/R (Figure 3c and i,
Supplementary Table S1c). Kim-1 levels peaked at 24 h
(Figure 3e and i) and returned to the levels persistently above
baseline at 96 and 120 h after reperfusion (Figure 3g and h,
Supplementary Table 1c). This time course correlated with
histological changes of the kidney marked by single-cell
necrosis and sloughing of cells in tubules at 9 h (Figure 3k)
followed by proximal tubular necrosis with associated
inflammation and cast formation at 18 and 24 h (Figure 3l)
and subsequently regeneration and restoration of damaged
epithelium at 120 h (Figure 3m). The amount of Kim-1
urinary excretion detected by RenaStick correlated well with
Kim-1 protein expression in the kidney (Figure 3o–q).
Modest elevations in BUN (B1.6-fold), SCr (B1.5-fold)
were observed at 9 h following reperfusion with a statistically
significant increase at 18 h for BUN (B2.1-fold) and SCr
(B2.4-fold) (Figure 3r and s).
Evaluation of human RenaStick in patients with or without
various forms of AKI
We tested the ability of RenaStick to identify human KIM-1
in samples from patients with and without AKI. Supplemen-
tary Table 2 shows the results of KIM-1 quantification using a
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Figure 2 | Evaluation of rat RenaStick to detect urinary Kim-1 in gentamicin-induced nephrotoxicity model. Urinary Kim-1
measurements using rat RenaStick (a–d), BUN and serum creatinine (e, f), and histological damage (g–i) following gentamicin-induced
kidney toxicity. Male Sprague Dawley rats received gentamicin sulfate at 0, 40, or 120 mg/kg/day (n¼ 5 rats per dose group) for 9 days, and
urine samples were collected on day 10 by keeping rats in metabolic cages. (a–c) Urinary Kim-1 was measured from each rat by mixing 70 ml
of urine sample with 70 ml of TRIS-buffered saline solution and adding it to the RenaStick sample well. Results were read in 15 min. (d) Each
RenaStick was scanned using a CAMAG Thin Layer Chromatography scanner and the densitometric units obtained were plotted. On day 10,
blood and kidney tissue were obtained from animals for evaluation of (e) blood urea nitrogen (BUN), (f) serum creatinine, and (g–i)
histomorphological evaluation of kidneys (hematoxylin and eosin staining). All fields were chosen from the cortex. Arrows in panels g and i
indicate sloughing of cells, tubular dilation, and necrosis. Bar represents 50 mm. *Represents statistically higher than control (Po0.05).
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Figure 4 | Detection of KIM-1 using human RenaStick in urine from patients with or without kidney injury. Urinary KIM-1
measurements using human RenaStick in (a–c) a cross-sectional study involving 24 patients with or without acute kidney injury and (d–f)
prospective study in two patients with cisplatin-induced kidney toxicity over time.
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Figure 3 | Detection of urinary Kim-1 using rat RenaStick in bilateral renal ischemia/reperfusion model. Urinary Kim-1 measurements
using rat RenaStick (a–i), kidney histopathology (j–m), immunohistochemistry for Kim-1 (n–q), and BUN and serum creatinine (r–s) over time
following 20 min of bilateral renal ischemia/reperfusion injury. Male Wistar rats were subjected to 0 (sham) or 20 min of bilateral ischemia by
clamping the renal pedicles for 20 min and then removing the clamps and confirming reperfusion. (a–h) Rats were placed in metabolic
cages and urine was collected at 6, 9, 18, 24, 48, 72, 96, and 120 h following reperfusion. Urinary Kim-1 was measured from each rat by
mixing 70 ml of urine sample with 70 ml of TRIS-buffered saline solution and adding it to the RenaStick sample well. Results were read in
15 min. (i) Each RenaStick was scanned using a CAMAG Thin Layer Chromatography scanner and the densitometric units obtained were
plotted. (j–q) Rats were killed at various times and blood and kidney tissue were collected. Representative photomicrographs of H&E-stained
kidney sections and immunohistochemistry for Kim-1 are presented from the following time points: (j and n) 0 h (sham control); (k and o)
9 h; (i and p) 24 h; (m and q) 120 h. All fields were chosen from the outer stripe of outer medulla (OSOM). Arrows in panels from k–m indicate
sloughing of cells, tubular dilation, and necrosis. Panels o–q show Kim-1 staining in the apical membrane of the proximal tubules in the
OSOM region. Bar represents 50mm. (r) Blood urea nitrogen (BUN) and (s) serum creatinine were measured over time following reperfusion.
*Represents statistically higher than sham-operated animals (Po0.05).
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microbead-based assay, and Figure 4a–c show the correspond-
ing results using RenaStick. Urinary KIM-1 band intensity was
significantly higher in AKI patients than in healthy volunteers
(Po0.05). The quantification between RenaStick and the
microbead-based assay was comparable, with a Pearson’s
correlation coefficient of 0.88 (Po0.0001) (data not shown).
Supplementary Table 3 and Figure 4d–f show how RenaStick
performs on serially collected urine from two patients who
developed postoperative AKI following cytoreductive surgery
with intraoperative local cisplatin administration for malignant
mesothelioma. In each patient, preoperative and 6 h samples
were negative according to RenaStick, and also measured below
800 pg/ml on the microbead-based assay. At 24 h, peak KIM-1
levels were identified by both techniques, with decreasing values
at subsequent time points.
The opportunity to use the same marker for both the
preclinical and clinical setting facilitates clinical monitoring
of toxicity that has been demonstrated at higher doses in
preclinical development or in a single test species when
human relevance is suspect. Rat RenaStick sensitively detects
two- to threefold increases in urinary Kim-1, levels which
have been shown to exceed the threshold defining early and
mild reversible kidney tubular injury by histopathology.5
Although relatively high doses of gentamicin were used in the
rodent model of kidney toxicity, we have shown earlier that
the pharmacological doses of gentamicin result in elevation
of urinary KIM-1 in humans above the lowest limit of
detection of human RenaStick (B0.8 ng/ml). Therefore, it is
anticipated that human RenaStick will be effective in
detecting KIM-1 in human AKI secondary to aminoglycoside
treatment. Human RenaStick sensitively detects KIM-1 levels
exceeding 800 pg/ml, which we showed to be an optimal
cutoff (75% sensitivity, 89% specificity) in a cross-sectional
study of patients with and without AKI, as defined by
changes in the less than optimal ‘SCr,’ which is not always
reliable as a marker of tubular injury.14 The levels measured
by a microbead-based assay were found to be comparable
with the levels using rat RenaStick (r2¼ 0.91) and human
RenaStick (r2¼ 0.88) (Po0.0001), suggesting that RenaStick
can replace the more cumbersome and time intensive ELISA-
based systems for quantification of KIM-1. Our results from
two patients undergoing surgery who received large doses of
cisplatin show the clinical applicability of RenaStick: levels of
KIM-1 were undetectable before and 6 h after surgery, and
became detectable (4800 pg/ml) at 24 h when they peaked and
subsequently declined. As urinary KIM-1 levels are undetectable
in rats or humans without any proximal tubular damage, the
RenaStick serves as a convenient, quick, and clear ‘yes or no’
diagnostic assay for kidney damage.
One limitation of RenaStick is the quantification of
absolute values of KIM-1. Because of the kidney’s ability to
dilute and concentrate the urine, levels of biomarkers are
often expressed as a ratio to the urinary concentration of
creatinine, which accounts for variations in urinary flow rate.
Creatinine dipsticks are available, and could be used along-
side KIM-1 to aid interpretation. Previous studies have
shown, however, that absolute levels of biomarkers may be as
useful as normalized values in detecting increases in kidney
tubular injury in rodents and patients.5,12
In summary, we report the development of the first point
of care diagnostic dipstick assay for a kidney toxicity
biomarker qualified by the FDA and EMEA. A point of care
device for detection of Kim-1 in urine should facilitate
predictive safety assessment in preclinical and clinical studies
and allow for monitoring of kidney tubular injury in many
clinical trials.18 In addition, the dipstick assay should allow
for the more effective identification of kidney status and the
development of effective strategies directed toward prevent-
ing kidney injury.
MATERIALS AND METHODS
Animals
All animals were maintained in their respective central animal
facility over wood chips free of any known chemical contaminants
under conditions of 21±11C and 50–80% relative humidity at
all times in an alternating 12 h light-dark cycle. Rats were fed
with commercial rodent chow (Teklad rodent diet no. 7012),
given water ad lib, and were acclimated for 1-week before use.
All animal maintenance and treatment protocols were in compliance
with the Guide for Care and Use of Laboratory animals as adopted
and promulgated by the National Institutes of Health and were
approved by respective Institutional Animal Care and Use Committees
(IACUC).
Experimental design for rat RenaStick evaluation
Cadmium-induced kidney toxicity. Male Sprague Dawley rats
(n¼ 4/group) weighing 275–300 g were maintained in individual
plastic cages. They received varying doses of CdCl2 (Cd dose of 0.6,
1.2, or 2.4 mg/kg for 5 days per week for 4 weeks) subcutaneously as
reported earlier.10 Control group animals (n¼ 4) received daily
injections of the 0.9% sodium chloride vehicle alone.
Gentamicin-induced kidney toxicity. Male Sprague Dawley
rats (265–316 g) received a daily intraperitoneal injection of either
vehicle (0.9% sodium chloride) or 40 or 120 mg/kg/day gentamicin
sulfate (n¼ 5 rats per dose group) for 9 days and were necropsied on
day 10.
Renal I/R. Fifty-six male Wistar (W) rats weighing approxi-
mately 270–300 g were anesthetized with an intraperitoneal injection
of pentobarbital sodium (30 mg/kg) and placed on a homeothermic
table to maintain core body temperature at 371C, by means of a
rectal probe attached to a temperature regulator which was in turn
attached to a homeothermic blanket. A midline laparotomy incision
was made, renal pedicles were isolated, and bilateral renal ischemia
was induced by clamping the renal pedicles for 0 or 20 min as
described previously.7 Occlusion was verified visually by change in
the color of the kidneys to a paler shade. Reperfusion commenced
when the clips were removed as confirmed by a blush reflective of
the return of oxygenated blood to the kidney. The rats were divided
into groups of eight rats each after 6, 9, 18, 24, 48, 72, 96, and 120 h
of reperfusion. A group of four rats underwent sham surgery and
served as controls. Rats (n¼ 4) per group were immediately placed
in metabolic cages at 221C. Individual urine samples were collected
at 6, 9, 18, 24, 48, 72, 96, and 120 h after reperfusion for analysis of
Kim-1. Another set of rats (n¼ 4) were euthanized by overdose of
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pentobarbital (200 mg/kg, intraperitoneal) at 6, 9, 18, 24, 48, 72, 96,
and 120 h after reperfusion.
To confirm the results obtained from RenaStick, urinary Kim-1
was measured using our previously described microbead-based
assay.5
Urine collection
Rats were placed in the standard metabolic cages and urine samples
were collected from individual animals into containers surrounded
by dry ice and were stored at 801C until thawing for urinalysis.
After the initial thawing at 221C, samples were placed on wet ice and
volume measurement was performed (precipitates were allowed to
settle by gravity and were discarded). In some cases, 2.5 ml urine
samples were used for routine clinical chemistry urinalysis (Roche
Modular Analyzer, Basel, Schweiz, Switzerland): manual specific
gravity, pH, protein, glucose, creatinine, occult blood, creatinine,
and ketones were measured. For the remaining urine volumes, small
aliquots were made and stored at 801C until biomarker analysis to
avoid repeated freeze-thaw cycles.
Blood collection and clinical chemistry
Rats were fasted overnight before necropsy and bled from the vena
cava with 2 ml collected into a serum separator tube and centrifuged
1500 g for 10 min at 41C. An additional 2 ml of collected blood
was placed into an EDTA collection tube and centrifuged 900 g for
15 min at 41C to isolate plasma. Plasma and serum samples were
stored at 801C until use. BUN (mg per 100 ml) and creatinine were
measured using a standard clinical chemistry analyzer (Roche-
Modular).
Histopathology
At necropsy, tissues were collected from Cd- or gentamicin-treated rats
for histology soon after the last blood collection and exsanguination.
Both kidneys (5 mm section including the papilla, cortex, and medulla)
were isolated from each animal and placed in 10% neutral buffered
formalin. In the renal I/R study, one kidney was perfused through the
left ventricle with phosphate-buffered saline (PBS) and then with 4%
paraformaldehyde lysine periodate for 10 min for histology. Tissues
were fixed for a minimum of 24 h, processed and embedded in
paraffin. Embedded tissues were cut into 4–6mm sections and stained
with hematoxylin and eosin. Tissues from control and treated animals
were examined with a light microscope.
Immunohistochemical or immunofluorescence visualization
of Kim-1
For immunohistochemistry, paraformaldehyde lysine periodate-fixed
tissue sections (in I/R injury study) (5mm) were deparaffinized in
xylene, dehydrated with a series of alcohol washes and then incubated
for 20 min at 951C in a citrate buffer solution (Zymed Laboratories,
no. 00-5000, South San Francisco, CA, USA). The samples were then
processed for visualization of Kim-1 using a monoclonal anti-rat
Kim-1 antibody (MARKE-2) using the same labeling protocol for
paraffin-embedded tissue samples as described earlier.7 For immuno-
fluorescence staining of Kim-1 in the Cd study, the sections were
thawed, washed with PBS, fixed in 201C methanol, and blocked
in 1.5% normal goat serum in PBS (blocking solution) for 30 min.
The sections were then incubated for 1 h with monoclonal anti-rat
Kim-1 antibody (MARKE-2) (5mg/ml) diluted in the blocking
solution. The sections were washed with PBS and incubated with
anti-mouse fluorescein isothiocyanate conjugated (1:75 dilution,
Pierce, Rockford, IL, USA) in PBS for 30 min. At the final step,
sections were washed with PBS and mounted with Vector Shield
mounting reagent (Vector, Burlingame, CA, USA) containing
12.5mg/ml 4,6-diamidino-2-phenylindole to identify nuclei. As a
negative control, the same concentration of mouse immuno-
globulin G (5mg/ml) was used for the primary antibody.
Selection of participants and urine sample collection
Urine samples from patients with and without elevated urinary
KIM-1 levels (41000 pg/ml) were obtained from our cross-sectional
study on urinary biomarkers of AKI.14 Urine samples had been
kept frozen at 801C and then thawed for quantitation by
RenaStick and microbead measurement of KIM-1 as described
earlier.14 Patients without elevated urinary KIM-1 levels were
healthy volunteers (n¼ 9) and critically ill patients with no
clinical evidence of AKI (n¼ 3). Patients with elevated urinary
KIM-1 levels had acute tubular necrosis (n¼ 7) and recent cardiac
catheterization (n¼ 3); two patients had tubular injury of unknown
etiology. Thresholds were chosen to maximize both sensitivity and
specificity.
Serial pre- and postoperative urine samples were also obtained
from two patients with postoperative AKI from cytoreductive
surgery with intraoperative local cisplatin administration for
treatment of malignant mesothelioma. Urine samples were obtained
preoperatively, 6 h postoperatively, and then every day for up to 5
days. The Institutional Review Board approved the protocols for
recruitment and sample collection.
Urine was collected from spontaneous voids or from indwelling
Foley catheters. Urine dipstick analysis was performed (Multistix 8
SG, Bayer Corporation, Tarrytown, NY, USA), followed by
centrifugation and microscopic examination of the urine sediment
(Olympus microscope). The urine supernatant was aliquoted into
1.8 ml eppendorf tubes and frozen within 2 h of collection at 801C.
At the time of assay, samples were thawed, vortexed, and centrifuged
at 14,000 r.p.m. at 41C, and the supernatant was pipetted for KIM-1
measurement.
Development and evaluation of direct lateral flow
immunochromatographic assay for measurement of Kim-1
Coupling of gold nanoparticles to Kim-1 capture antibo-
dies. Forty milimicrometer gold nanoparticles obtained from
BioAssay Works were coated with mouse monoclonal anti Kim-1
antibody (MARKE-1)7 or rabbit polyclonal antibody against human
KIM-114 by adjusting the pH of the gold particles with a bicarbonate
buffer to slightly above the isoelectric point of the Kim-1 antibody.
Approximately 200 molecules of antibody were coated onto each
gold sphere, blocked with bovine serum albumin and sprayed on
polyester ribbon. The ribbon was air-dried at 371C for 2 h and stored
in a desiccated chamber. BioAssay Works’ nitrocellulose membrane
was striped with 2 mg/ml solution of another epitopically distinct
anti-Kim-1 antibody at a rate of 1 ml/cm2. A control line of goat
anti-mouse Kim-1 antibody, for rat RenaStick, or anti-rabbit KIM-1
antibody, for human RenaStick, was also striped down at the same
rate. The striped down membrane and air-dried ribbon were
assembled in overlapping manner on a plastic laminate (see
Supplementary Figure S1a). Strips were cut 4 mm wide and placed
in plastic immunochromatographic housing.
Evaluation of the assay. The positive and negative Kim-1
urine samples were diluted twofold in a TRIS-buffered saline
solution and 150 ml of the mixture was added to the sample well of
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the immunochromatographic housing. The results were read within
15 min. Kim-1 antigen detection levels in urine greater than 500 pg/
ml (or 800 pg/ml for human KIM-1) were realized with a
dose–response relationship covering a three-log range. The inter-
assay variability of less than 10% was determined by adding diseased
urine samples containing low (1.3 ng/ml), medium (8.6 ng/ml), and
high (19 ng/ml) levels of Kim-1 to nine RenaSticks (n¼ 3 each)
(data not shown).
Quantitation of Kim-1 band intensities
The strips were read using a CAMAG Thin Layer Chromatography 3
Scanner, CAMAG Scientific Inc., Wilmington, NC, USA. The
CAMAG scanner is designed for densitometric measurement of
thin-layer chromatograms and other objects up to 200 200 mm in
size. The scanner was set to read at a wavelength of 546 in the light
absorption-mode at a scanning speed of 5 mm/s. The scanning
produces peaks and the peak height correlates with the signal. The band
intensity units were represented on Y axis in the respective injury
models with respect to either dose or time on X axis using Prism 4
software, GraphPad Software Inc., La Jolla, CA, USA. Statistical
comparison between control and treated was obtained by two-tailed
Student’s t-test and a P-value less than 0.05 was assessed as statistically
significant. Comparisons between quantitated Kim-1 band intensity
and log-transformed Kim-1 measurements by the microbead assay
were assessed by the Pearson’s correlation coefficient. RenaStick was
developed at Bioassayworks using epitopically distinct antibodies raised
in our laboratory as previously described (reference 7). An extensive
characterized and evaluation of RenaStick was then performed in our
laboratory.
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SUPPLEMENTARY MATERIAL
Table S1. Urinary Kim-1 values measured by microbead-based xMAP
technology in three mechanistically different kidney injury models
caused by (a) cadmium, (b) gentamicin or (c) 20 min bilateral
ischemia/reperfusion injury.
Table S2. Urinary KIM-1 values measured by microbead-based xMAP
technology in patients with or without acute kidney injury.
Table S3. Urinary KIM-1 values measured by microbead-based xMAP
technology in patients with acute kidney injury following cisplatin
administration.
Figure S1. Characteristics of rat RenaStick.
Figure S2. Characteristics of human RenaStick.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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